The impact of semaglutide on liver outcomes in patients with or at risk of MASH: a dose and duration response meta-analysis of randomized trials.

Diabetol Metab Syndr · 2025 · PMC12642090 · PMID 41286982

Europe PMC DOI

hedged sentence

0.4900

closest p · 9.8× alpha

0.4900

boldest claim

The sentences

did not reach statistical significanceP = 0.49not close (p > 0.1)

In contrast, the pooled result for improvement in liver fibrosis (defined as 3 1-stage reduction) did not reach statistical significance (RR = 1.18, 95%CI: 0.74 to 1.88, P = 0.49; Fig. 3 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.